IMDX Insight Molecular Diagnostics Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: IMDX

Price (delayed)

$6.6

Market cap

$213.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.5

Enterprise value

$187.25M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 16

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular ...

Highlights
Insight Molecular Diagnostics's equity has surged by 66% QoQ
The company's EPS has surged by 62% YoY and by 9% QoQ
IMDX's quick ratio has surged by 118% since the previous quarter but it is down by 35% year-on-year
Insight Molecular Diagnostics's gross profit has shrunk by 56% QoQ and by 50% YoY
The revenue has shrunk by 52% QoQ and by 49% YoY
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.oncocyte.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of IMDX

IMDX stock price

How has the Insight Molecular Diagnostics stock price performed over time
Intraday
9.45%
1 week
1.07%
1 month
26.2%
1 year
125.26%
YTD
-12%
QTD
101.22%

Financial performance

How have Insight Molecular Diagnostics's revenue and profit performed over time
Revenue
$1.95M
Gross profit
$1M
Operating income
-$48.74M
Net income
-$47.84M
Gross margin
51.3%
Net margin
-2,454.6%
The operating margin has shrunk by 98% QoQ and by 64% YoY
IMDX's net margin has dropped by 98% since the previous quarter and by 62% year-on-year
Insight Molecular Diagnostics's gross profit has shrunk by 56% QoQ and by 50% YoY
The revenue has shrunk by 52% QoQ and by 49% YoY

Price vs fundamentals

How does IMDX's price correlate with its fundamentals

Growth

What is Insight Molecular Diagnostics's growth rate over time

Valuation

What is Insight Molecular Diagnostics stock price valuation
P/E
N/A
P/B
N/A
P/S
116.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
96.08
The company's EPS has surged by 62% YoY and by 9% QoQ
Insight Molecular Diagnostics's equity has surged by 66% QoQ
The price to sales (P/S) is 165% more than the last 4 quarters average of 40.3 and 131% more than the 5-year quarterly average of 46.2
The revenue has shrunk by 52% QoQ and by 49% YoY

Efficiency

How efficient is Insight Molecular Diagnostics business performance
The company's return on sales has shrunk by 98% QoQ and by 62% YoY
IMDX's return on assets is down by 23% year-on-year and by 7% since the previous quarter
IMDX's ROIC is down by 16% since the previous quarter but it is up by 6% year-on-year

Dividends

What is IMDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMDX.

Financial health

How did Insight Molecular Diagnostics financials performed over time
IMDX's total assets is 21% smaller than its total liabilities
IMDX's quick ratio has surged by 118% since the previous quarter but it is down by 35% year-on-year
The current ratio has soared by 100% from the previous quarter but it has contracted by 32% YoY
IMDX's debt is 129% greater than its equity
The debt to equity has dropped by 185% year-on-year and by 164% since the previous quarter
Insight Molecular Diagnostics's equity has surged by 66% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.